Valneva, Bavarian Nordic Announce Marketing and Distribution Partnership

Valneva and Bavarian Nordic have signed a binding term sheet to establish a partnership for the marketing and distribution of their commercial products. The partnership will provide both companies with additional critical mass, significant commercial synergies and a market leadership position in the specialty vaccine industry.

Under the agreed terms, Valneva will commercialize Bavarian Nordic’s marketed vaccines leveraging its commercial infrastructure in Canada, UK, France and Austria. Valneva will also take responsibility for Belgium and the Netherlands where it will set up new commercial operations. Bavarian Nordic will commercialize Valneva’s marketed products in Germany and Switzerland. The partnership includes vaccines that protect against rabies, Japanese Encephalitis, tick-borne encephalitis and cholera.

The agreement follows Bavarian Nordic’s recent acquisition of two commercial vaccines from GlaxoSmithKline. The transition from current arrangements will commence later this year and through 2021 in line with existing distribution agreements. Valneva expects limited additional revenues in 2020 with more material impact from 2021 onwards.

 “We are excited to join forces with Bavarian Nordic to continue to build our commercial business and to enhance our product offering to our customers. This partnership provides excellent synergy for both companies as well as greater breadth in our commercial portfolios,” Thomas Lingelbach, CEO of Valneva, said.

“We are pleased to collaborate with Valneva in the ongoing commercialization of our business. Valneva’s strong commercial presence combined with our accelerated establishment of a commercial infrastructure allows us to implement the right go-to-market strategy in the different markets and will provide mutual benefits by adding complementary products to both companies’ portfolios,” Paul Chaplin, President & CEO of Bavarian Nordic, said.